AMZNprintsminutestrendsdividendsdrawdownsP/E 28.4macronarrativesvolatilitybuybackssentiment+0.8%marginsMSFTPMI 52.1momentumdividendsflowsPMI 52.1digeststhreadsvolatilityearnings callsvolumesβ 1.24breakoutsnewsflow2s10sliquidityheadlines−1.2%breakoutsnoiseGOOGLbuybacksrevisionstrendsPMI 52.1briefstickersnoiseGDPsentimentchattertranscriptsGOOGLsentimentvolatilitybuybacksMSFTwhispersMETAsessionsyield curves13FfuturesdowngradesPMI 52.1headlinesthe tapeflowsdowngradesfutures+0.8%earnings callstranscriptsclosesgammacatalystsrevisionsvolatilitysentimentchatter+2.41%earnings callssentimentfilingstrends10y 4.21%cyclesbuybackswiresspx 0dtewhisperstickersQ3trendsnewsflowearnings callsWTI 78.2sentimentnoisethreadsrumorsnarrativesFOMCconsensusestimatesmomentumYoY +18%tickersmomentumprintsβ 1.24revisions

momentumheadlines52w hipositioning2s10sfilingstrendsprintstrendsmacrocyclesnoise2s10smacroQ3narrativesheadlinesflowscyclesnarrativesspreadstranscriptsdowngradesupgradeswhisperswhispersminutesthe tapeNDXfuturesminutesyield curves52w hithe tapeFOMCcatalystsbriefsthe tapeNVDAguidancetrends52w hidrawdowns2s10swhispersmomentumdrawdownsbuybacks

PCEliquiditysentimentbreakoutsdowngradesP/E 28.4threadsAAPLSPXvolatilityNDXflowscyclesliquidityestimatesEPS 4.12

CAI · NASDAQ · Biotechnology

Caris Life Sciences (CAI)

Delivers tissue and blood molecular profiling for oncology care and biopharma research.

$31.77

After hours+0.29 (+0.92%)

At close$31.48(+2.71%)

In millions of USD, except per-share figures

In millions	Q2 FY21Jun 2021	Q3 FY21Sep 2021	Q1 FY24Mar 2024	Q2 FY24Jun 2024	Q3 FY24Sep 2024	Q4 FY24Dec 2024	Q1 FY25Mar 2025	Q2 FY25Jun 2025	Q3 FY25Sep 2025	Q4 FY25Dec 2025	Q1 FY26Mar 2026	Q2 FY26Jun 2026
Revenue	86	101	81	100	102	130	121	181	217	293	216	264
Cost of revenue	43	47	55	62	57	59	64	68	69	72	75	84
Gross profit	43	54	26	38	44	71	57	114	148	221	141	180
	10	12	118	−29	105	108	115	96	115	133	136	153
Research & development	0	0	34	25	28	27	23	25	22	32	5	32
	10	12	84	80	78	81	92	107	93	101	105	120
Selling & marketing	0	0	38	39	37	0	39	42	41	44	45	54
General & administrative	10	12	45	41	41	0	53	64	52	57	60	67
Other expenses	0	0	0	−134	0	0	0	−36	0	0	26	0
Operating income	51	66	−92	67	−61	−37	−58	18	33	88	5	27
	−11	−12	−19	−133	−7	0	−45	−90	−8	−6	−6	−28
Interest income	0	0	2	3	2	1	1	2	7	7	7	7
Interest expense	11	0	9	14	14	13	13	19	14	11	13	9
Other non-operating income	0	0	10	120	0	0	32	71	−5	−5	−7	18
Income before tax	40	55	−111	−66	−68	−37	−103	−72	24	82	−1	−1
Income tax expense	2	4	0	0	0	0	0	0	0	0	0	0
Net income from continuing operations	38	51	−111	−66	−68	−37	−103	−72	24	82	−1	−1
Net income	38	51	−111	−66	−68	−37	−103	−72	24	82	−1	−1
EPS, basic	$2.20	$2.95	−$0.53	−$0.35	−$0.33	−$0.22	−$0.40	−$1.93	$0.09	$0.29	−$0.00	−$0.00
EPS, diluted	$2.17	$2.92	−$0.53	−$0.35	−$0.33	−$0.22	−$0.40	−$1.87	$0.08	$0.28	−$0.00	−$0.00
Weighted average shares, basic	17	17	255	255	281	281	255	268	282	282	283	283
Weighted average shares, diluted	17	18	255	255	281	281	255	276	297	290	283	283
EBITDA	80	88	−84	−41	−50	−28	−83	−46	43	98	17	15
Depreciation & amortization	29	33	18	12	11	9	7	6	5	4	5	7
EBIT	51	0	−102	−53	−61	−37	−90	−53	38	93	12	9